GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oxurion NV (OTCPK:TBGNF) » Definitions » GF Score

Oxurion NV (Oxurion NV) GF Score : 23/100 (As of Jun. 07, 2024)


View and export this data going back to . Start your Free Trial

What is Oxurion NV GF Score?

Oxurion NV has the GF Score of 23, which implies that the company might have Worst future performance potential, or not enough data.

The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.

GF Score takes following five key aspects into consideration:

1. Financial Strength : 1/10
2. Profitability Rank : 2/10
3. Growth Rank : 1/10
4. GF Value Rank : 0/10
5. Momentum Rank : 1/10

Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.

Based on research and backtesting result, GuruFocus believes Oxurion NV might have Worst future performance potential, or not enough data.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Competitive Comparison of Oxurion NV's GF Score

For the Biotechnology subindustry, Oxurion NV's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Oxurion NV's GF Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oxurion NV's GF Score distribution charts can be found below:

* The bar in red indicates where Oxurion NV's GF Score falls into.


Oxurion NV  (OTCPK:TBGNF) GF Score Explanation

Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:

GF Score Performance Potential and All-in-One Screener Examples (1)
91 - 100Highest outperformance potential
81 - 90Good outperformance potential
71 - 80Likely to have average performance
51 - 70Poor future performance potential
0 - 50Worst future performance potential, or not enough data

(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.

Oxurion NV GF Score Related Terms

Thank you for viewing the detailed overview of Oxurion NV's GF Score provided by GuruFocus.com. Please click on the following links to see related term pages.

Oxurion NV (Oxurion NV) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oxurion NV (OTCPK:TBGNF) » Definitions » GF Score
Comparable Companies
XBRU:ACCB XBRU:INCLU XBRU:ZEN XBRU:MCC XBRU:BAS OCSE:NOVO B VRTX REGN ASX:CSL MRNA XKRX:207940 XKRX:068270 XBRU:UCB BNTX XBRU:ARGX ALNY OCSE:GMAB BGNE BMRN INCY
Traded in Other Exchanges
TG4:Germany OXUR:Belgium
Address
Gaston Geenslaan 1, Leuven, BEL, B-3001
Website
https://www.oxurion.com
Oxurion NV is a clinical stage biopharmaceutical company developing next generation standard of care ophthalmic therapies, which are designed to improve and better preserve vision in patients with retinal disorders including diabetic macular edema (DME). The Group's research and development facilities are located in Belgium .The Company is engaged in the development of drugs to treat back-of-the-eye diseases, more specifically, ophthalmologic pharmaceuticals to treat vascular retinal disorders, specifically DME.